Athlete Hannah Babalola says she was told to use the toilet without an aisle chair or leave Cape Town to Amsterdam flight The Dutch airline KLM has offered “sincere apologies” to a Paralympic athlete who was denied access to an onboard wheelchair during a long-haul flight so she could go to the toilet. The cabin crew on the flight later called the police after the request from Hannah Babalola, 37,...
Athlete Hannah Babalola says she was told to use the toilet without an aisle chair or leave Cape Town to Amsterdam flight The Dutch airline KLM has offered “sincere apologies” to a Paralympic athlete who was denied access to an onboard wheelchair during a long-haul flight so she could go to the toilet. The cabin crew on the flight later called the police after the request from Hannah Babalola, 37, who is paraplegic and competes in track events, for the wheelchair, known as an aisle chair as it is narrow enough to be used inside a plane. They first handed her a written notice, headed: “Unacceptable conduct and final warning on behalf of the captain of this plane.” Continue reading...
Costco Wholesale (NASDAQ: COST) reported blowout earnings for the 2026 fiscal third quarter (ended May 10). The warehouse retailer is demonstrating accelerating sales growth and is even more popular as consumers seek the best prices amid rising inflation rates. As outstanding as the report was, it wasn't enough to boost the stock, though, which fell after the results were released. The market's be...
Costco Wholesale (NASDAQ: COST) reported blowout earnings for the 2026 fiscal third quarter (ended May 10). The warehouse retailer is demonstrating accelerating sales growth and is even more popular as consumers seek the best prices amid rising inflation rates. As outstanding as the report was, it wasn't enough to boost the stock, though, which fell after the results were released. The market's been worried about a slowdown happening as inflation persists, even though the impact so far has only been positive for Costco. However, it just provided another round of excellent news for Costco shareholders , and the stock is rising again. Continue reading
Indonesia may raise interest rate again to shield the rupiah and curb market volatility, according to analysts, after the central bank’s surprise tightening on Tuesday helped the currency rebound from record lows and boosted stocks. Bank Indonesia lifted the benchmark BI-Rate by 25 basis points to 5.5%, more than a week ahead of its next scheduled meeting, after the rupiah hit fresh lows and breac...
Indonesia may raise interest rate again to shield the rupiah and curb market volatility, according to analysts, after the central bank’s surprise tightening on Tuesday helped the currency rebound from record lows and boosted stocks. Bank Indonesia lifted the benchmark BI-Rate by 25 basis points to 5.5%, more than a week ahead of its next scheduled meeting, after the rupiah hit fresh lows and breached the 18,000-per-dollar level last week. The currency extended gains to 0.8% against the greenback, the most in nine months. Read more: Indonesia Delivers Shock Rate Hike to Reverse Market Sell Off The rate hike should also support Indonesian stocks in the long run, even as some analysts warn that higher borrowing costs may weigh on returns in the near term. The benchmark Jakarta Composite Index rose as much as 6.8% in afternoon trading, putting it on track for its first advance in five days. Still, the gauge is down more than 30% this year, making it the worst-performing major stock benchmark globally. In the bond market, the selloff intensified , with yields rising across the curve. Bank Indonesia is aiming to push yields higher to enhance the appeal of the bonds to foreign portfolio investors. Here’s what market participants said after the surprise interest-rate hike: BNY ( Wee Khoon Chong ) “Bank Indonesia’s offcycle interest-rate hike is the clearest signal of its resolve to steady the rupiah. It is hard to say that the total 75bps rate hike so far would be sufficient to halt IDR depreciation pressure considering the on-going external market volatility” “We see chance for further rate hike at the normal scheduled meeting on June 18 if the rupiah fails to stabilize” Credit Agricole CIB ( Jeffrey Zhang ) Policy hikes will not reverse the rupiah’s weakness, although it should help to curb excess volatility from future events “We don’t rule out BI hiking later in 2H 2026, but the timing and magnitude would be highly dependent on the impact from the coming event shocks, i...
The new report by the Uppsala Conflict Data Program said the massacres in El Fasher pushed one-sided violence in Africa to its highest levels since the Rwandan genocide in 1994.
The new report by the Uppsala Conflict Data Program said the massacres in El Fasher pushed one-sided violence in Africa to its highest levels since the Rwandan genocide in 1994.
Martin Philip/iStock via Getty Images I am optimistic about Immunome ( IMNM ) because I believe the market has yet to consider the company a broad targeted oncology platform with a near-term commercial anchor—although the market currently views it as limited to its desmoid tumor story. I do not think the key part of this thesis is merely that varegacestat was successful in achieving what are consi...
Martin Philip/iStock via Getty Images I am optimistic about Immunome ( IMNM ) because I believe the market has yet to consider the company a broad targeted oncology platform with a near-term commercial anchor—although the market currently views it as limited to its desmoid tumor story. I do not think the key part of this thesis is merely that varegacestat was successful in achieving what are considered strong results from a phase three study. Rather, I believe the most critical component of this thesis is that Immunome has used business development in a focused way to build a portfolio of products—including varegacestat (submitted NDA), ROR1 ADC, FAP-targeted radioligand therapy, and numerous other ADCs targeting solid tumors. In addition to Immunome's acquisition of varegacestat via its purchase of Ayala in 2024, the company also completed the Morphimmune merger—at which time Clay Siegall, the former co-founder and CEO of Seagen, joined Immunome as CEO. In my opinion, both of these developments matter as they show Immunome has evolved beyond a small biotech with a single product and moved toward a targeted oncology capital allocation vehicle where management will acquire or license products that have sufficient clinical or technological evidence to warrant expedited advancement toward commercialization. The recent positive results from the RINGSIDE trial represent the first major success validating management's strategy. Cash Runway Immunome's financial statements are best viewed as an indicator of the company's remaining runway, its ability to accelerate its pipeline, and the risk of future dilution. Because there were no revenues from collaborations in the first quarter of 2026 (compared to $2.9 million for the prior-year period), this indicates that all prior performance obligations related to AbbVie have now been recognized. The company’s research and development expenses were $46.4 million in Q1-2026, compared to $36.9 million in the prior-year period. Additio...
Apple shares were edging down early on Tuesday as investors digested its artificial-intelligence plans, which raised some questions among analysts. Apple stock was down 0.3% at $300.74 in premarket trading.
Apple shares were edging down early on Tuesday as investors digested its artificial-intelligence plans, which raised some questions among analysts. Apple stock was down 0.3% at $300.74 in premarket trading.
骏创科技公告，为完善海外产能布局，开拓东南亚市场，满足海外市场配套需求，公司拟以自有资金与新加坡全资子公司XCONN DEVELOPMENT PTE. LTD.共同出资300万美元在泰国设立子公司XCONN Energy Technologies (THAILAND) Co., Ltd.。拟新设公司注册资本500万元泰铢，公司持股比例为1%，新加坡子公司持股比例为99%。
骏创科技公告，为完善海外产能布局，开拓东南亚市场，满足海外市场配套需求，公司拟以自有资金与新加坡全资子公司XCONN DEVELOPMENT PTE. LTD.共同出资300万美元在泰国设立子公司XCONN Energy Technologies (THAILAND) Co., Ltd.。拟新设公司注册资本500万元泰铢，公司持股比例为1%，新加坡子公司持股比例为99%。
hapabapa Roche ( RHHBY ) said it will proceed with its planned €600M investment in a new diagnostics production facility in Penzberg, Germany, despite concerns over the German government's proposed healthcare cost-cutting measures, according to a Reuters report. The company said construction on the site, its largest single investment in Germany, remains on track for completion in 2027. "The cabine...
hapabapa Roche ( RHHBY ) said it will proceed with its planned €600M investment in a new diagnostics production facility in Penzberg, Germany, despite concerns over the German government's proposed healthcare cost-cutting measures, according to a Reuters report. The company said construction on the site, its largest single investment in Germany, remains on track for completion in 2027. "The cabinet decision is creating a new degree of uncertainty regarding investments, research, and production decisions in Germany," said Daniel Steiners, CEO of Roche Pharma AG. The decision contrasts with recent moves by Eli Lilly ( LLY ) and Boehringer Ingelheim , which have scaled back planned investments in Germany, citing planned government healthcare cost cuts. The CEO added that the government's plans risk significant economic damage with little benefit to the long-term sustainability of the healthcare system and said the parliamentary process offers a final opportunity to keep Germany on a reliable path. More on Roche Holding Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript Roche Holding AG (RHHBY) Presents at American Society of Clinical Oncology (ASCO) Annual Meeting 2026 - Slideshow Roche Holding AG (RHHBY) Analyst/Investor Day Transcript Nurix surges 43% on up to $3B cancer drug deal with Roche Zealand phase 2 data on petrelintide shows durable weight loss
当前，Coding Agents 在软件工程领域一路高歌猛进，科学家们看到此场景，也不禁寄予厚望： AI 智能体何时能以同样的速度，帮人类攻克药物设计、病毒监控与生物学建模的重重难关？ 然而，一个残酷的现实是，AI 在生物学领域的发展要比编程领域慢得多…… 近日，Anthropic 发表了一篇新科学博客 ——《为生物学智能体铺平道路》（Paving the way for agents in bi...
当前，Coding Agents 在软件工程领域一路高歌猛进，科学家们看到此场景，也不禁寄予厚望： AI 智能体何时能以同样的速度，帮人类攻克药物设计、病毒监控与生物学建模的重重难关？ 然而，一个残酷的现实是，AI 在生物学领域的发展要比编程领域慢得多…… 近日，Anthropic 发表了一篇新科学博客 ——《为生物学智能体铺平道路》（Paving the way for agents in biology），文章指出： 阻碍生物学 AI Agent 爆发的瓶颈，根本不在于大模型底座的推理能力不够强，而在于人类现有的生物学数据基础设施实在是太落后了。 因此，如果希望 AI Agent 真正参与生物学研究，生物数据基础设施必须变得更适合 Agent 使用。 这篇文章由 Laura Luebbert 撰写，她是一位生物学家与机器学习研究员。 有意思的是，Laura Luebbert 透露，这篇博客是在 Karpathy 官宣加入 Anthropic 之前一周就完成的，因为文中部分内容涉及 Karpathy ，还担心 Anthropic 会不会觉得这篇「Karpathy 味」太重。没想到的是，就在她把初稿发给 Anthropic 的同一天，他们就官宣了…… 下面，我们就来详细看一下，这篇文章是如何分析的？ 现有生物数据基础设施，对 Agent 来说太难走了 作者用了一个很有意思的类比， 让 AI Agent 去操作生物数据基础设施，有点像开车穿过一座在汽车出现前就建好的老城： 这座城市也许很美，规划也有其用心之处，但里面到处是狭窄、曲折的街道，现代车辆难以顺畅通行。对应到生物数据领域，就是各种特有的文件格式、分散的数据库，以及一次性的检索脚本。 当然，你也可以试着给这座城市补上交通标志、停车场，甚至偶尔拓宽几条道路，但它最基本的布局仍然难以通行，原因在于它原本就是为另一种交通方式设计的。 相比之下，软件基础设施几乎天然就适合「汽车」，也就是 Agent 使用：铺好的道路、清晰的车道、标准化信号，以及支持从起点到终点快速通行的系统，也就是版本控制、文档清晰的 API 和包管理器。 因此，Coding Agent 的发展速度明显快于生物学 Agent。 软件领域通常具备结构化的数字工作流和可靠接口，而计算生物学中用于数据检索和验证的基础设施，往往脆弱、异构，并且高度依赖具体流...
The history of megacap initial public offerings shows that the stocks usually slump in the first year of trading. But upcoming listings from SpaceX , Anthropic and OpenAI are big enough and systemically important enough to the market that those analogies may not apply. All which poses a crucial timing question for investors: When is the right moment to buy shares in one of the upcoming mega-tech I...
The history of megacap initial public offerings shows that the stocks usually slump in the first year of trading. But upcoming listings from SpaceX , Anthropic and OpenAI are big enough and systemically important enough to the market that those analogies may not apply. All which poses a crucial timing question for investors: When is the right moment to buy shares in one of the upcoming mega-tech IPOs? “These behemoth IPOs will rapidly take up both the market share of benchmarks and the mindshare of retail investors,” said Max Gokhman , senior vice president at Franklin Templeton Investment Solutions. Looking at 30 major technology IPOs over the past 15 years, Truist Wealth found that they averaged a maximum decline of 55% in the first year of trading. Forward returns skewed negative at the six-month mark as well, according to Truist calculations. There are numerous possible reasons for the weakness, including low public share floats and added selling pressure from the expiration of lockups preventing early investors from selling right away. The difference, however, is the IPOs that are coming aren’t your normal megacap deals. SpaceX, which is officially known as Space Exploration Technologies Corp., is seeking $75 billion in what’s set to be the largest IPO of all time , valuing the company at about $1.8 trillion. Anthropic has held private funding rounds that value it at $965 billion, and OpenAI is worth $852 billion based on its own fundraising. All three jumbo-sized offerings are expected to result in market values of more than $1 trillion or at least very close to it. There are currently only 11 companies in the S&P 500 Index with market capitalizations above $1 trillion. “I have never been asked more about an IPO than SpaceX from our retail clients and advisers,” said Matt Stucky , chief portfolio manager of equities at Northwestern Mutual Wealth Management Co. “That’s interesting, but at the same time it’s also a little concerning just from a risk management p...
The devil’s in the details. | Image: Cath Virginia / The Verge, Donut Labs Donut Lab's solid-state battery claims have been thoroughly debunked by Ryan Inis Hughes on his popular Ziroth YouTube channel . According to Hughes, Donut Lab has engaged in deliberate, calculated deception by claiming to have a solid-state battery ready for mass production . In reality, it's nothing more than a standard l...
The devil’s in the details. | Image: Cath Virginia / The Verge, Donut Labs Donut Lab's solid-state battery claims have been thoroughly debunked by Ryan Inis Hughes on his popular Ziroth YouTube channel . According to Hughes, Donut Lab has engaged in deliberate, calculated deception by claiming to have a solid-state battery ready for mass production . In reality, it's nothing more than a standard lithium-ion design. Hughes' investigation got an assist from whistleblower Lauri Peltola , the former Chief Commercial Officer (CCO) of Nordic Nano Group - the company supposedly partnered with Donut Lab to manufacture the batteries. Hughes says he also turned to "over 20 independent battery experts," including Julian Zahnow … Read the full story at The Verge.